A new target for ImmTAC
OXFORD, U.K. & CONSHOHOCKEN, Pa.—Immunocore has shared news that GlaxoSmithKline has chosen a third target as part of the companies’ ongoing cancer discovery collaboration to identify multiple novel targets not addressable with antibody-based technologies. The agreement was originally announced in 2013, and Immunocore is working on two ImmTAC programs under the deal, with the lead program progressing toward an IND this year with potential in non-small cell lung cancer, bladder cancer, synovial sarcoma, melanoma and ovarian cancer. Immunocore will be producing a novel ImmTAC molecule against the recently chosen target, which plays a role in several cancers.
According to Dr. Bent Jakobsen, Immunocore’s chief scientific officer, “ImmTAC molecules are relevant across a wide range of cancer types and have the ability to tackle solid ‘cold’ low mutation rate tumors—the majority of tumors which are difficult for other immuno-oncology drugs to address. We look forward to beginning work on this additional program with GSK in oncology.”